Articles by Joan Levy, PhD - MRA Chief Science Officer
100,000 Americans Estimated to be Diagnosed with Invasive Melanoma in 2024
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for...
Clinical Trials to Watch: December 2023
Treatment of advanced melanoma has dramatically improved over the past decade with 16 new therapies approved by the Food and Drug Administration (FDA). Even with these treatment advances, 50% of patients with advanced melanoma will either not respond to any of these treatments or their disease will progress creating a...
Nearly 100,000 Americans Estimated to be Diagnosed with Melanoma in 2023
Each January, the American Cancer Society (ACS) releases updated estimates about trends in new cancer cases and deaths in its annual report, Cancer Facts and Figures. This report highlights the estimated incidence (number of new cases), prevalence (number of people alive today with a history of cancer), and survival statistics for cancer in the United States.
About the Author
Joan Levy, PhD - MRA Chief Science Officer
Joan Levy, PhD, serves as the Chief Science Officer for the Melanoma Research Alliance. In this role she works with MRA’s scientific team and leadership to set the scientific vision for the organization, and oversees all aspects of MRA's Research Program – including grants, the RARE Registry, and special projects. Joan has more than 30 years of experience in oncology research in academic, pharmaceutical, and disease foundation settings.
Prior to joining MRA, Joan was Director of Research at the Chordoma Foundation and provided oversight of research activities, in particular focusing on programs involving identification of new therapeutic targets, further development of the Foundation's Drug Screening Program, and advancement of new drugs and combination approaches into the clinic. For ten years Joan also led a variety of research programs at the Multiple Myeloma Research Foundation ranging from spearheading different grant programs to working closely with their affiliate consortium on large genomics projects, registries and coordinating early clinical trials between consortium sites and industry partners. Before her work at the different oncology foundations, Joan coordinated an oncology pipeline of early drug discovery projects at Bayer Pharmaceuticals.
Joan received her BS in Biology from the State University of New York at Stony Brook and earned a PhD in Biochemistry from the University of Vermont College of Medicine. She completed two postdoctoral fellowships in oncology research focusing on oncogenes and signal transduction pathways at the Rockefeller University and at the State University of New York at Stony Brook.